MedPath

A study to compare the efficacy of gabapentin plus amitryptiline with amitryptiline alone for management of chemotherapy induced peripheral neuropathy.

Phase 4
Conditions
Health Condition 1: G620- Drug-induced polyneuropathy
Registration Number
CTRI/2017/07/009109
Lead Sponsor
ESI Institute of Pain Management ESI Hospital Sealdah
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients with cancer having neuropathic pain.

2. Patient on WHO ladder therapy for control of cancer related pain.

Exclusion Criteria

1. Patients with unstable cardiovascular, respiratory, hepatic or hematological disease or psychological disorder.

2. Patient having diabetes, HIV, Guillain-Barré syndrome, CIDP, radiculopathy.

3. Alchoholic,drug abuse patient.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath